FFA
VINC

Farther Finance Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Farther Finance Advisors’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$3 – 4460
2024
Q4 		$3 Hold
1
– – ﹤0.01% 3986
2024
Q3 		$7 Buy
+1
New +$14 ﹤0.01% 3961

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Farther Finance Advisors's VINC Position: Q1 2025 in Review

Farther Finance Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 1 share — an estimated $3 sold.

Farther Finance Advisors first reported a position in VINC in Q3 2024 and held it in 2 quarters. The position peaked at $7 in Q3 2024. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

  • Farther Finance Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 1 Vincerx Pharma, Inc. Common Stock share in Q1 2025, an estimated $3.
  • Farther Finance Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2024 and held it in 2 quarters.
  • Farther Finance Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $7 in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Farther Finance Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.